pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
NovaPharmaNews editorial coverage mentioning Novo Nordisk A/S — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Novo Nordisk A/S — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Novo Nordisk A/S — regulatory, clinical, and market analysis.
Weight Loss Medications in 2026: GLP-1 Market Shift
Novo wins UK approval as race to launch weight-loss pill intensifies
Novo Nordisk won UK approval for its oral Wegovy weight-loss pill, making the UK the first European market to allow access. The decision strengthens Novo’s lead in the oral GLP-1 race as Eli Lilly advances orforglipron.
Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Novo Nordisk’s CagriSema phase 3 update shows strong obesity and diabetes efficacy, but the obesity readout fell short of top-tier expectations. This plan focuses on the catalyst, the comparator data, and what BD teams and investors should watch next.
EMA Endorses Novo Nordisk's Wegovy for Weight Loss
The European Medicines Agency has endorsed Novo Nordisk's Wegovy for weight loss, marking a significant milestone in obesity treatment. This analysis explores the implications for investors and pharma teams.
Big Pharma Q1 Growth Insights: Lilly, AbbVie, J&J, AZ Lead the Charge
This article analyzes the recent Q1 growth trends in Big Pharma, focusing on key players and their market implications.